Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

ClinicalTrials.gov ID: NCT01668797

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01668797. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy of brexpiprazole compared with placebo as maintenance treatment in adults with schizophrenia.

Study identification

NCT ID: NCT01668797
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Enrollment: 524 participants

Conditions and interventions

Conditions

Acute Schizophrenia

Interventions

Brexpiprazole Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2012 (Type not available)
Primary completion: Jan 2015 (Actual)
Completion: Feb 2015 (Actual)
Last update posted: Jan 13, 2017

2012 – 2015

United States locations

U.S. sites: 14
U.S. states: 9
U.S. cities: 13

Facility	City	State	ZIP	Site status
Not listed	Anaheim	California	92805	—
Not listed	Cerritos	California	90703	—
Not listed	Garden Grove	California	92845	—
Not listed	San Diego	California	92102	—
Not listed	San Diego	California	92103	—
Not listed	Tampa	Florida	33613	—
Not listed	Hoffman Estates	Illinois	60169	—
Not listed	Saint Charles	Missouri	63304	—
Not listed	St Louis	Missouri	63141	—
Not listed	North Platte	Nebraska	69101	—
Not listed	Las Vegas	Nevada	89102	—
Not listed	Memphis	Tennessee	38119	—
Not listed	Dallas	Texas	75231	—
Not listed	Richmond	Virginia	23230	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01668797, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 13, 2017 · Synced Nov 14, 2026